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Abstract 
Purpose 
To evaluate whether the rate of Gleason score (GS) upgrade on final pathology, the 
rate of positive surgical margins (PSM) and the rate of biochemical recurrence (BCR) 
after radical prostatectomy (RP) were different if prostate biopsy (PB) was graded by 
community pathologists (CP) as compared to specialized uro-pathologists (UP). 
Methods 
A consecutive series of patients undergoing RP in our institution between 2005 and 
2013 was retrospectively reviewed. Any GS higher or lower in RP specimen as 
compared to PB GS was defined as GS upgrade or downgrade, respectively. 
Additionally, stratification for the new ISUP 2014 grading system was performed. 
Predictors of GS upgrade and PSMs and prognostic parameters for BCR were 
assessed by stepwise logistic regression models and by multivariable Cox regression 
analyses, respectively. 
Results 
A total of 786 patients were available for analysis and median follow-up was 36 
months (1-101 months). A GS upgrade was found in 345 patients (43.9%) and a GS 
downgrade in 91 patients (11.6%). Discordance between PB GS and RP GS was 
significantly more frequent when grading had been performed by a CP (50.5% 
upgrade, 9.0% downgrade) than by a UP (33.1% upgrade, 15.7% downgrade, 
p<0.001). CP evaluation was an independent predictor for GS upgrade (odds ratio 
[OR] 1.91, p<0.001) and for PSMs (OR 1.69, p=0.003), as well as an independent 
predictor of BCR (hazard ratio [HR] 1.65, p=0.028). 
Conclusions 
Pathologic evaluation of PBs by a dedicated UP should be recommended to reduce 
the rate of biopsy undergrading, PSM and BCR after RP. 
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Introduction 
Since its first description in the 1960s, the Gleason grading system has been 
accepted as grading standard and as the most accurate histopathological factor for 
the prognosis of prostate cancer (PC) patients [1]. Grading of prostate biopsy (PB) 
specimens is an important factor for counselling and decision making in men 
diagnosed with PC. The choice to perform active surveillance, nerve-sparing radical 
prostatectomy (RP), a pelvic lymphadenectomy or androgen deprivation therapy in 
addition to external beam radiation are all based on preoperative risk parameters 
such as PB Gleason score (GS) and pre-treatment prostate specific antigen values 
(PSA) [2-4]. Thus, incorrect grading of PB specimens can result in inappropriate 
management of patients. Undergrading can lead to treatment delays or 
undertreatment (positive survival margins, no lymph node resection) requiring 
secondary therapeutic options and compromising quality of life and survival. 
 
Several studies have shown that discordance between PB GS and RP GS appears in 
almost 50% of all cases [5]. Histopathological Gleason grade evaluation can 
significantly affect the accuracy of tumor classification [6]. Different levels of 
experience and skills of pathologists have been reported to be associated with GS 
discordance between PB and RP specimens [7-10]. However, the clinical significance 
of incorrect PB GS grading remains to be elucidated. In this study, we aimed to 
evaluate the accuracy of the PB GS grading depending on the diagnosing pathologist 
(community vs. uro-pathologist) and the prognostic impact on the oncological 
outcome in a contemporary RP series.  
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Materials and methods 
Patient selection and data collection 
All men who underwent robotic-assisted RP (RARP) between May 2005 and 
December 2013 in our tertiary care academic center were retrospectively identified. 
Patients diagnosed with PC after ultrasound-guided transrectal PB performed in our 
center or externally by community urologists were eligible for this study. Men with PC 
diagnosed in specimens of transurethral resection of the prostate (TURP), or 
diagnosed after magnet resonance imaging (MRI)-guided biopsy and men who 
received neoadjuvant androgen deprivation treatment were excluded from further 
analysis. Electronic hospital charts were reviewed to collect peri- and postoperative 
data. Additionally, data were retrieved from referring urologist or patient’s general 
practitioners if follow-up was not performed in our center. 
 
Patients were divided into two groups, depending on whether their PB specimen had 
been evaluated in our institution by a minimum of two pathologists (uro-pathologist 
[UP] group)  - of whom at least one expert in urologic pathology -, or by pathologists 
in the community (community pathologist [CP] group). PB GS, core numbers and 
numbers of positive cores were retrieved from the respective pathology reports. PB 
slides of patients who were referred to our center by community urologists were not 
reviewed before RARP at our institution.  
 
Surgical procedure and pathological analysis 
RARP was performed by five experienced prostate surgeons using the three and 
four-arm daVinci® Surgical System (Intuitive Surgical Inc., Sunnyvale, CA). Bilateral 
extended pelvic lymph node dissection (EPLND) was performed as described earlier 
in patients with either a PSA level of ≥10 ng/ml or a preoperative GS of ≥7 [11]. A 
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nerve-sparing procedure was usually performed bilaterally in patients with cT1/2 PC 
and PB GS ≤7 and unilaterally in selected patients with GS 8 and small tumor volume 
identified on PB on the contralateral side.  
 
All RARP specimens were processed at our institution. Comprehensive pathologic 
analysis was performed using standardized whole-mount sections [12].  
 
Statistical analyses 
SPSS version 22.0 (IBM Corp., Armonk, NY, USA) was used for statistical analyses. 
All two-sided p-values < 0.05 were considered statistically significant. The CP and 
the UP group were compared using Fisher’s exact test for categorical variables and 
the Mann–Whitney U test for continuous variables. 
 
PB GS were compared with the GS of their respective RP specimen individually. A 
RP GS higher or lower than the PB GS was defined as GS upgrade or downgrade, 
respectively. Concordance between PB GS and GS of the surgical specimen was 
calculated using the Cohen kappa test (correction for agreement expected by 
chance) [13]. Additionally, stratification according to the recent ISUP 2014 prognostic 
grade groups (PGG) revision was performed [1,14,15]. 
 
Subgroup analyses evaluating clinically significant up- and downgrading for the 
following three treatment groups were performed: GS 5-6 = potential candidate for 
active surveillance [16], GS 7 = eligible for nerve-sparing [2], and GS 8-10 = high risk 
tumors who should have undergone RP and EPLND without NS [2,16] according to 
our institute's guidelines.  
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Logistic regression models adjusting for preoperative parameters were built to 
identify predictive factors for GS upgrades.  
 
BCR was defined as PSA value ≥0.1 ng/ml with subsequent confirmation after 
reaching a PSA nadir ≤0.1 ng/ml postoperatively. The predictive impact of pre- and 
postoperative parameters on PSM and BCR rates was assessed by a stepwise 
logistic regression and a Cox regression model, respectively.  
 
To assess differences in prognostic accuracy of the CP vs. UP PB grading, Kaplan-
Meier analyses of BCR-free survival (BCRFS) were performed and estimates were 
compared between the CP and UP group using the log-rank test. Subgroups were 
formed according to the D’Amico criteria [17]. 
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Results 
Of 826 patients undergoing RARP, 40 were excluded due to PC diagnosis by TURP 
(n=22) or MRI-guided biopsy (n=11) or due to neoadjuvant androgen deprivation 
therapy (n=7) resulting in 786 patients eligible for the final analysis. Pre-, intra- and 
postoperative data of these patients are summarized in Table 1. 
 
Patients in the CP group had higher preoperative PSA levels (mean 10.1 vs. 8.1 
ng/mL), had more often palpable tumors (31% vs. 22%) and fewer cores were taken 
during PB (mean 9.7 vs. 10.7). The distribution of PB GS was not significantly 
different between the two groups.  
 
Final pathology revealed significantly higher rates of extraprostatic extension, more 
GS 8-10 tumors and more PSMs in patients initially diagnosed by a CP. Even when 
stratified for pathological tumor stage and final GS, persistently higher rates of PSMs 
could be observed in the CP group. The PSM rate for Gleason 8-10 tumors was 
49.5% in the CP group and 15.2% in the UP group (p < 0.001).  
 
Table 2 and 3 show the number and percentage of upgrades and downgrades 
between biopsy and RARP specimen. The overall GS concordance measured by 
Kappa was fair (0.273) in the CP group and moderate (0.411) in the UP group. 
Significantly higher rates of overall and clinically significant upgrades were found 
when biopsies were graded by a CP.  
 
Table 4 displays the results of the uni- and multivariable logistic regression analyses. 
A higher preoperative PSA level, a lower number of biopsy cores as well as grading 
by a CP predicted GS upgrade in the univariable analysis (Table 4a). In the 
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multivariable analysis, a higher PSA level and grading by a CP remained significant 
predictors of GS upgrade. The second model assessed the risk of PSMs (Table 4b). 
In the multivariable analysis, a RP GS of 7, pT3 tumor stage and CP grading 
remained independent predictive factors for PSMs.  
 
Median follow-up time was 36 (range 1-101) months. A postoperative PSA nadir of 
<0.1 ng/ml was not reached by 50 (10.3%) men in the group of patients graded by a 
CP any by 17 (7.5%) men in the group of patients graded by a UP (p = 0.025). This 
difference remained significant in a subgroup analysis stratified for risk groups (data 
not shown). Table 5 displays the results of the Cox regression analysis. In the 
univariate model, all variables but nerve-sparing were significantly associated with a 
lower BCRFS rate. In the multivariable model, grading by a CP remained an 
independent predictor of BCR with a hazard ratio (HR) of 1.65 (p = 0.028). 
 
The Kaplan-Meier analyses of BCRFS comparing the CP and UP group are shown 
on Figure 1 A-D. For low-risk patients (n=177) a higher BCR rate was detected in the 
CP group (Figure 1-B). Comparison of these estimates with survival analyses based 
on final pathology showed that the UP PB GS 6 curve resembled more the RP GS 6 
curve than the CP GS 6 curve did (Figure 1-B).  
 
In the intermediate risk group (n=319), comparison of PB GS 7 BCRFS with 
estimates based on finally pathology showed that the UP PB GS 7 curve resembled 
more the RP GS 7 curve than the CP PB GS 7 curve did (Figure 1-C).  
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A significantly lower BCRFS rate could be observed for patients with a RP GS of 8-10 
and preoperative PSA level of <20 ng/ml (n=92) when biopsies had been graded by a 
CP (Figure 1-D).  
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Discussion 
The present study is the first to evaluate the association between pathology report 
origin and concordance between PB and RP GS, as well as its impact on oncological 
outcome in a contemporary series of patients treated by RARP for PC. We were able 
to show that PB GS undergrading was significantly more frequent if PB grading had 
been performed by a CP compared to a UP. In addition, PB GS grading by a CP was 
an independent predictor of worse oncological outcome. Men in the CP group more 
often had PSM, postoperative PSA persistence and BCR compared to the UP group.  
 
In 1992, DF Gleason himself raised the problem of non-dedicated pathologists having 
the tendency to not recognize small amounts of higher tumor grade [18]. This might 
explain why in the present study more than half (54.5%) of the tumors with a Gleason 
8-10 on final pathology were not recognized as such by the CP compared to 37% 
missed by the UP. Steinberg and colleagues backed Gleason’s statement in 1997 
with reporting a higher rate of GS upgrade between the biopsy and the prostatectomy 
specimen when the biopsy material was analyzed in non-academic settings (37% vs. 
28%) [7]. Kuroiwa et al. reported in 2011 a 16% higher rate of undergrading by CP 
[10]. Notably, their studies included data from the pre ISUP 2005 era and did not 
assess the prognostic impact of the pathologist on oncological outcome.  
 
An improved concordance rate is not only a theoretical advantage, but is of clinical 
relevance. Undergrading of PB samples leads to an underestimation of the actual 
disease burden and can have considerable consequences for therapeutic decision-
making after diagnosis of PC. Active surveillance, brachytherapy and new therapeutic 
approaches such as focal therapy are currently considered inappropriate treatment 
options for most patients with intermediate or high risk PC [16,19]. Furthermore, the 
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extent of surgical resection (LND, nerve-sparing) but also the indication for 
concomitant androgen deprivation with radiotherapy is based on preoperative risk 
stratification [2-4] and can have significant impact on patient’s quality of life. 
Additional treatments may become necessary or opportunities for cure may be 
missed in patients with misclassified tumors. Our subgroup analysis for clinically 
significant undergrading revealed higher rates of misclassification of patients when 
biopsies were graded by a CP compared to a UP based on inclusion criteria for 
active surveillance (64.2% vs. 48.7%) and recommendations for nerve-sparing 
(12.6% vs. 6.7%).  
 
Accordingly, based on our hypothesis that an inaccurate PB GS compromises an 
adequate surgical approach and therefore the oncological outcome, we could show 
that grading by a CP is an independent predictor of PSMs. A surgeon 
underestimating the tumor might select inadequate patients for nerve-sparing and 
perform a more extensive preservation of surrounding structures. The impact of GS 
underestimation on PSM rates has been described before; Corocoran et al. reported 
in a retrospective analysis significantly higher PSM rates in upgraded tumors than in 
corresponding concordant tumors [20]. The PSM rate in undergraded Gleason 3+4 
tumors were significantly higher than in accurately diagnosed counterparts. In the 
present investigation, nearly half of the patients with a RP GS of 8-10 had PSMs 
when PBs were graded by a CP, compared to only 15% in patients graded by UP. 
This observation gains importance considering that more than every second patient 
with a RP GS 8-10 had been assigned a lower GS preoperatively by a CP. 
Consequently, the observed rate of nerve-sparing was also significantly higher in this 
group compared to the group of patients whose PB cores had been graded by a UP. 
This further indicates the important role of surgeon’s decisions in the high risk 
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situation for a favorable surgical resection of the tumor and possible consequences of 
undergrading for the oncological outcome (Figure 1-D). 
 
The assessment of BCRFS was performed in this study for two reasons: one motive 
was to evaluate the impact of preoperative parameters including the grading 
pathologist on a more objective criterion of midterm oncological outcome. The 
second reason was to address the issue of an innate bias: our pathologic department 
was grading both of the specimens (PB and RP). This might have led to a better 
correlation between the UP PB GS and RP GS. Therefore, we investigated the 
prognostic accuracy of the PB and RP GS for BCRFS and discriminated which of the 
PB GS (CP or UP) was a more precise reflection of tumor behavior. 
 
Kaplan-Meier analysis indicated RP GS 5-6 as an excellent predictor of tumor 
aggressiveness with a 5-y estimated BCRFS of 96%. This is in line with large 
reported series and the expected behavior of these tumors [21]. With an estimated 
5y-BCRFS of 90% in the group of low-risk tumors (based on PB GS), grading by UP 
achieved a higher predictive accuracy than grading by a CP (5y-BCRFS of 83%).  
 
A similar constellation was observed in the intermediate risk group. While the better 
outcome of patients with a PB GS 7 graded by a UP over CP is probably due to the 
higher rate of downgrading at RP, the Kaplan-Meier curve of CP-graded patients with 
PB GS 7 estimates a BCRFS-rate more similar to patients with a RP GS 8-10 than 
RP GS 7, hinting at the larger proportion of actual higher GSs in this group. 
 
This study has limitations. It was not possible to distinguish whether the grading in 
2005 and 2006 had been performed according to the classic system or according to 
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the ISUP 2005 consensus. It can be reasonably assumed that the modernized 
Gleason grading scheme was more rapidly adopted by dedicated UPs than among 
CPs. However, the high number of patients and a period of almost nine years 
strengthen the hypothesis of permanent and significant difference in the accuracy of 
Gleason grading in the two groups. Furthermore, there were statistically significant 
differences in the preoperative parameters of the two groups. One potential 
explanation of these differences is that community urologists do refer patients with 
more advanced tumors to academic centers for surgery. To overcome this problem, 
we performed multivariable logistic and cox regression analyses and subclassification 
of patients into risk groups. Finally, a retrospective evaluation of an accurate biopsy 
technique is not feasible. We analyzed the number of biopsy cores, which was 
slightly lower for patients diagnosed by a CP. We further assume that a median of 10 
cores in the CP and 12 cores in the UP graded group exceeded the critical cut-off of 
6 cores for a significantly increased risk of GS upgrade [6] and had therefore limited 
impact on the accuracy of the grading in this study. 
 
Conclusion 
Dedication of pathologists not only affects the rate of discordance but also the 
oncological outcome of patients treated for localized prostate cancer. We strongly 
recommend prostate biopsy specimen to be reviewed by a dedicated uro-pathologist 
to improve the concordance between prostate biopsy and radical prostatectomy 
Gleason score, which in turn allows to choose the most appropriate treatment option 
and eventually results in a better oncological outcome.  
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Figure legends 
Fig. 1 Kaplan-Meier analyses for biochemical recurrence-free survival. (A) All 
Patients stratified for origin of pathology report. (B) Patients with a PSA of <10 
ng/mL, clinical T1 stage and PB GS of 4-6 stratified for origin of pathology report and 
compared to concordant and higher RP GS. (C) Patients with a PSA of <20 ng/mL, 
clinical T1-2 stage and PB GS of 7 stratified for origin of pathology report and 
compared to concordant and higher RP GS. (D) Patients with a PSA <20 ng/mL and 
a RP GS of 8-10 (final pathology) stratified for origin of pathology report 
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Table 1. Patient characteristics 
    Total cohort (n=786) 
Community 
pathology 
(n=487) 
Uro-pathology 
(n=299) p* 
Preoperative data           
Age, y median (IQR) 64 (58–68) 63 (58–67) 64 (59–68) 0.008 
Preoperative PSA, ng/mL median (IQR) 7.1 (4.9–10.9) 7.5 (5.3–11.1) 6.8 (4.4–10.0) <0.001 
Clinical T stage cT1 528 (72.0%) 317 (68.6%) 211 (77.9%) 0.007 
 
cT2 205 (28.0%) 145 (31.4%) 60 (22.1%) 
 Number of PB cores median (IQR) 10 (8–12) 10 (8–12) 12 (8–12) <0.001 
Number of positive PB cores median (IQR) 3 (2–5) 3 (2–5) 3 (1–5) 0.430 
PB Gleason Score  5-6  317 (40.3%) 204 (41.9%) 113 (37.8%) 0.248 
 
7a (3+4) 260 (33.1%) 152 (31.2%) 108 (36.1%) 
 
 
7b (4+3) 104 (13.2%) 73 (15.0%) 31 (10.4%) 
  8-10  105 (13.4%) 58 (11.9%) 47 (15.7%)  
Intraoperative data 
     Lymph node dissection All 522/786 (66.4%) 326/487 (66.9%) 196/299 (65.6%) 0.698 
 
Gleason 5-6 32/149 (21.5%) 18/81 (22.2%) 14/68 (20.6%) 0.844 
 
Gleason 7 355/492 (72.2%) 218/307 (71.0%) 137/185 (74.1%) 0.533 
 
Gleason 8-10 135/145 (93.1%) 90/99 (90.9%) 45/46 (97.8%) 0.170 
Nerve sparing All 510/785 (65%) 331/487 (68.0%) 179/298 (60.1%) 0.026 
 
Unilateral 268/785 (34.1%) 162/487 (33.3%) 106/298 (35.6%) 
 
 
Bilateral 242/785 (30.8%) 169/487 (34.7%) 73/298 (24.5%) 
 
 
PB Gleason 5-6 247/316 (78.2%) 164/204 (80.4%) 83/112 (74.1%) 0.203 
 
RP Gleason 5-6 124/148 (83.8%) 70/81 (86.4%) 54/67 (80.6%) 0.376 
 
PB Gleason 7 238/364 (65.4%) 153/225 (68.0%) 85/139 (61.2%) 0.212 
 
RP Gleason 7 328/492 (66.7%) 218/307 (71.0%) 110/175 (59.5%) 0.010 
 
PB Gleason 8-10 25/105 (23.8%) 14/58 (24.1%) 11/47 (23.4%) 1.000 
 RP Gleason 8-10 58/145 (40%) 43/99 (43.4%) 15/46 (32.6%) 0.275 
Postoperative data 
     pT stage pT2a-c  578 (73.5%) 345 (70.5%) 233 (78.0%) 0.029 
 
pT3ab  206 (26.5%) 141 (28.9%) 65 (22.7%) 
 
 
pT4 2 (0.3%) 1 (0.2%) 3 (0.3%) 
 Gleason Score 5-6  149 (19.0%) 81 (16.6%) 68 (22.7%) 0.026 
 
7a (3+4) 331 (42.1%) 196 (40.2%) 135 (45.2%) 
 
 
7b (4+3) 161 (20.5%) 111 (22.8%) 50 (16.7%) 
 
 
8-10  145 (18.4%) 99 (20.3%) 46 (15.4%) 
 Positive margin status  All 237 (30.2%) 169 (34.7%) 68 (22.7%) <0.001 
 
pT2 129 (22.3%) 88 (25.5%) 41 (17.6%) 0.025 
 
pT3 108 (51.9%) 81 (57%) 27 (40.9%) 0.037 
 
Gleason 5-6 22/149 (14.8%) 16/81 (19.8%) 6/68 (8.8%) 0.068 
 
Gleason 7 159/492 (32.3%) 104/307 (33.9%) 55/185 (29.7%) 0.371 
 
Gleason 8-10 56/145 (38.6%) 49/99 (49.5%) 7/46 (15.2%) <0.001 
Months follow-up, m median (IQR) 36 (19–59) 37 (17–59) 36 (22–58) 0.842 
IQR: interquartile range, SD: standard deviation, PB: prostate biopsy, RP: radical prostatectomy. 
* p-values ≤0.05 are marked in bold. 
 
Table 2. Gleason Score up- and downgrades stratified by origin of pathology report 
    Total cohort             (n=786) 
Community 
pathology (n=487) 
Uro-pathology    
(n=299) p* 
Gleason Score shift     
Upgrade 345/786 (43.9%) 246/487 (50.5%) 99/299 (33.1%) <0.001 
Downgrade 91/786 (11.6%) 44/487 (9.0%) 47/299 (15.7 %) 0.006 
Concordance (GS) 0.324 0.273 0.411 <0.0011 
Concordance (GS 5-6, 7, 8-10) 0.396 0.355 0.467 <0.0011 
Clinically significant Gleason Score shift for potential active surveillance candidates (GS 5-6 vs. 7-10) 
Upgrade of PB. GS 5-6 186/317 (58.7%) 131/204 (64.2%) 55/113 (48.7%) 0.009 
Downgrade of PB GS 7-10 18/469 (3.8%) 8/283 (2.8%) 10/186 (5.4%) 0.218 
 PB GS 7 18/364 (4.9%) 8/225 (3.6%) 10/139 (7.2%)    PB GS 8-10  0/105 (0%) 0/58 (0%) 0/47 (0%)   
Clinically significant Gleason Score shift for nerve-sparing (GS 5-7 vs. 8-10) 
 Upgrade of PB. GS 5-7 71 /681 (10.4%) 54/429 (12.6%) 17/252 (6.7%) 0.019 
 
PB GS 5-6  17/317 (5.4%) 13/204 (6.4%) 4/113 (3.5%) 
 
 
PB GS 7 54/364 (14.8%) 41/225 (18.2%) 13/139 (9.4%) 
 Downgrade of PB GS 8-10 31/105 (29.5%) 13/58 (22.4%) 18/47 (38.3%) 0.088 
GS: Gleason score, PB: prostate biopsy. 
* p-values ≤0.05 are marked in bold. 
1 Kappa statistic 
 
Table 3. Radical prostatectomy grades stratified by biopsy Gleason scores and tumor stage 
  PB GS 4-6 (PGG 1) 
 
PB GS 3+4=7 (PGG 2) 
 
PB GS 4+3=7 (PGG 3) 
 
PB GS 8 (PGG 4) 
 
PB GS 9-10 (PGG 5) 
RP  GS 
all CP UP   all CP UP   all CP UP   all CP UP 
 
all CP UP 
5-6 131 (41.3) 73 (35.8) 58 (51.3) 
 
15 (5.8) 7 (4.6) 8 (7.4) 
 
3 (2.9) 1 (1.4) 2 (6.5) 
 
0 (0) 0 (0.0) 0 (0.0) 
 
0 (0) 0 (0.0) 0 (0.0) 
3+4=7 127 (40.1) 86 (42.2) 41 (36.3) 
 
159 (61.2) 89 (58.6) 70 (64.8) 
 
31 (29.8) 17 (23.3) 14 (45.2) 
 
12 (18.5) 3 (7.9) 9 (33.3) 
 
2 (5.0) 1 (5.0) 1 (5.0) 
4+3=7 42 (13.2) 32 (15.7) 10 (8.8) 
 
60 (23.1) 39 (25.7) 21 (19.4) 
 
42 (40.4) 31 (42.5) 11 (35.5) 
 
14 (21.5) 9 (23.7) 5 (18.5) 
 
3 (7.5) 0 (0.0) 3 (15.0) 
8 11 (3.5) 8 (3.9) 3 (2.7) 
 
15 (5.8) 8 (5.3) 7 (6.5) 
 
13 (12.5) 10 (13.7) 3 (9.7) 
 
12 (18.5) 5 (13.2) 7 (25.9) 
 
5 (12.5) 3 (15.0) 2 (10.0) 
9-10 6 (1.9) 5 (2.5) 1 (0.9) 
 
11 (4.2) 9 (5.9) 2 (1.9) 
 
15 (14.4) 14 (19.2) 1 (3.2) 
 
27 (41.5) 21 (55.3) 6 (22.2) 
 
30 (75.0) 16 (80.0) 14 (70.0) 
Total 317 (100) 204 (100) 113 (100) 
 
260 (100) 152 (100) 108 (100) 
 
104 (100) 73 (100) 31 (100) 
 
65 (100) 38 (100) 27 (100) 
 
40 (100) 20 (100) 20 (100) 
pT2 277 (87.4) 174 (85.3) 103 (91.2)   190 (73.1) 105 (69.1) 85 (78.7)   68 (65.4) 48 (65.8) 20 (64.5)   29 (44.6) 12 (31.6) 17 (63.0) 
 
14 (35.0) 6 (30.0) 8 (40.0) 
pT3a 27 (8.5) 19 (9.3) 8 (7.1) 
 
57 (21.9) 37 (24.3) 20 (15.5) 
 
21 (20.2) 17 (23.3) 4 (12.9) 
 
22 (33.8) 17 (44.7) 5 (18.5) 
 
17 (42.5) 7 (35.0) 10 (50.0) 
pT3b 11 (3.5) 10 (4.9) 1 (0.9) 
 
13 (5) 10 (6.6) 3 (2.8) 
 
15 (14.4) 8 (11.0) 7 (22.6) 
 
14 (21.5) 9 (23.7) 5 (18.5) 
 
9 (22.5) 7 (35.0) 2 (10.0) 
pT4 2 (0.6) 1 (0.5) 1 (0.9) 
 
0 (0) 0 (0) 0 (0) 
 
0 (0) 0 (0) 0 (0) 
 
0 (0.0) 0 (0.0) 0 (0.0) 
 
0 (0.0) 0 (0.0) 0 (0.0) 
Total 317 (100) 204 (100) 113 (100) 
 
260 (100) 150 (100) 108 (100) 
 
104 (100) 73 (100) 31 (100) 
 
65 (100) 38 (100) 27 (100) 
 
40 (100) 20 (100) 20 (100) 
RP: radical prostatectomy, GS: Gleason score, PGG: Prognostic Grade Group [1, 14, 15], PB: prostate biopsy, CP: community pathologist, UP: uro-pathologist. 
 
      
 
Table 4. Uni- and multivariable logistic regression models to predict (a) Gleason score upgrade from 
biopsy to radical prostatectomy and (b) positive surgical margin status 
        a. Univariable   Multivariable  
Parameter OR 95% CI p-value   OR 95% CI p-value 
Uro-pathologist 1.00 - - 
 
1.00 - - 
Community pathologist 2.06 1.53-2.8 <0.001 
 
1.91 1.40-2.61 <0.001 
Age ≤64 y 1.00 - - 
 
- - - 
Age >64 y 0.99 0.75-1.31 0.943 
 
- - - 
PSA <10 ng/ml 1.00 - - 
 
1.00 - - 
PSA ≥10 ng/ml 1.84 1.35-2.5 <0.001 
 
1.81 1.31-2.5 <0.001 
PB cores ≥10 1.00 - - 
 
1.00 - - 
PB cores <10 1.47 1.10-1.96 0.01 
 
1.32 0.98-1.78 0.07 
No. of positive PB cores 1.01 0.96-1.07 0.627 
 
- - - 
cT1 1.00 - - 
 
- - - 
cT2 0.90 0.65-1.25 0.537 
 
- - - 
b. Univariable   Multivariable 
Parameter OR 95% CI p-value   OR 95% CI p-value 
Uro-pathologist 1.00 - - 
 
1.00 - - 
Community pathologist 1.81 1.3-2.5 <0.001 
 
1.69 1.20-2.38 0.003 
PSA <10 ng/ml 1.00 - - 
 
1.00 - - 
PSA ≥10 ng/ml 1.78 1.28-2.46 0.001 
 
1.21 0.84-1.74 0.302 
PB cores ≥10 1.00 - - 
 
- - - 
PB cores <10 1.08 0.79-1.48 0.65 
 
- - - 
RP Gleason Score <7 1.00 - - 
 
1.00 - - 
RP Gleason Score =7 2.76 1.69-4.5 <0.001 
 
2.03 1.21-3.4 0.007 
RP Gleason Score >7 3.63 2.07-6.38 <0.001 
 
1.57 0.82-3.0 0.173 
cT2 1.00 - - 
 
- - - 
cT3 1.38 0.98-1.95 0.065 
 
- - - 
pT2 1.00 - - 
 
1.00 - - 
pT3 3.76 2.69-5.26 <0.001 
 
3.28 2.23-4.81 <0.001 
No nerve-sparing 1.00 - - 
 
- - - 
Unilateral nerve-sparing 0.68 0.47-0.97 0.036 
 
- - - 
Bilateral nerve-sparing 0.68 0.47-0.99 0.042 
 
- - - 
OR: odds ratio, 95% CI: 95% confidence interval, PB: prostate biopsy, RP: radical prostatectomy. 
 * p-values ≤0.05 are marked in bold.             
 
Table 5.  Uni- and multivariable Cox regression analysis of predictors for biochemical recurrence free 
survival 
  Univariable   Multivariable 
Parameter HR 95% CI p-value   HR 95% CI p-value 
Uro-pathologist 1.00 - - 
 
1.00 - - 
Community pathologist 2.21 1.42-3.43 <0.001 
 
1.65 1.06-2.6 0.028 
PSA <10 ng/ml 1.00 - - 
 
1.00 - - 
PSA ≥10 ng/ml 1.52 1.02 – 2.27 0.041 
 
0.85 0.55-1.30 0.439 
RP Gleason Score <7 1.00 - - 
 
1.00 - - 
RP Gleason Score =7 4.00 1.82-8.70 0.001 
 
2.66 1.20-5.87 0.016 
RP Gleason Score >7 10.70 4.78-24.2 <0.001 
 
5.18 2.18-12.3 <0.001 
cT1 1.00 - - 
 
1.00 - - 
cT2 1.72 1.16 – 2.56 0.007 
 
1.63 1.09-2.45 0.018 
pT2 1.00 - 
  
1.00 - - 
pT3 6.17 4.22 – 9.03 <0.001 
 
3.65 2.40-5.55 <0.001 
Negative surgical margin 1.00 - - 
 
1.00 - - 
Positive surgical margin 2.99 2.06 – 4.35 <0.001 
 
2.16 1.46-3.20 <0.001 
No nerve-sparing 1.00 - - 
 
- - - 
Unilateral nerve-sparing 0.80 0.51-1.27 0.345 
 
- - - 
Bilateral nerve-sparing 0.84 0.53-1.32 0.449  - - - 
HR: hazard ratio, 95% CI: 95% confidence interval, RP: radical prostatectomy.     
 * p-values ≤0.05 are marked in bold.             
 
